Drug survival of secukinumab for psoriasis in a real-world setting

Erica B. LeeJohn A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA;

Mina AminSchool of Medicine, University of California, Riverside, Riverside, CA, USA;

Alexander EgebergDepartment of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark;

http://orcid.org/0000-0001-8257-1816

Jashin J. WuDepartment of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USACorrespondence[email protected]

References

Egeberg A, Ottosen MB, Gniadecki R, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509–519.
PubMed Web of Science ®Google Scholar
Huang YYM, Ruth JS, Hsu S. Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks. J Am Acad Dermatol. 2016;75:e169
PubMed Web of Science ®Google Scholar
Georgakopoulous JR, Ighani A, Phung M, et al. Drug survival of secukinumab in real-world plaque psoriasis patients: a 52-week, multicenter, retrospective study. J Am Acad Dermatol. 2018;78(5):1019–1020. [Epub ahead of print]
PubMed Web of Science ®Google Scholar
Van den Reek JMPA, van Vugt LJ, van Doorn MBA, et al. Initial results of secukinumab drug survival in patients with psoriasis: a multicenter daily practice cohort study. Acta Derm Venerol.. 2018; Feb 6. [Epub ahead of print]
PubMed Web of Science ®Google Scholar
Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favorable safety profile in patients with moderate to severe psoriasis through 5 years of treatment (SCULPTURE extension study). J Eur Acad Dermatol Venereol. 2018; Feb 14. [Epub ahead of print]
Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Drug survival of secukinumab for psoriasis in a real-world setting

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Drug survival of secukinumab for psoriasis in a real-world setting

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date